Form 4: Nurix CSO Gwenn Hansen Granted 20,000 RSUs

Nurix Therapeutics' Chief Scientific Officer, Gwenn Hansen, was granted 20,000 Restricted Stock Units, vesting over two years.

Summary

• Gwenn Hansen, Chief Scientific Officer of Nurix Therapeutics, Inc. (NRIX), was granted 20,000 Restricted Stock Units (RSUs).
• The transaction date for this grant was October 14, 2025.
• Each RSU represents a contingent right to receive one share of Nurix Therapeutics' common stock.
• The RSUs were granted at a price of $0.
• The RSUs will vest on the second anniversary of the grant date, specifically October 14, 2027, contingent upon Ms. Hansen's continuous service to the Issuer.
• Following this transaction, Gwenn Hansen beneficially owns 20,000 derivative securities (RSUs).

Sentiment

Score: 6

Explanation: The RSU grant is a routine executive compensation event, generally viewed as neutral to slightly positive as it aligns management incentives with shareholder interests and aids in retention, without indicating any immediate operational or financial changes.

Positives

• The RSU grant aligns the Chief Scientific Officer's long-term interests with those of shareholders, incentivizing sustained performance and company growth.
• This form of equity compensation serves as a retention tool, encouraging key management personnel to remain with the company.
• The grant is a standard component of executive compensation packages, reflecting ongoing commitment to leadership.

Negatives

• The vesting of these RSUs will result in future dilution for existing shareholders as new shares of common stock are issued.

Risks

• The RSUs are subject to forfeiture if the reporting person's continuous service to the Issuer terminates prior to the vesting date.
• The value of the RSUs upon vesting is dependent on the future market price of Nurix Therapeutics' common stock, introducing market risk.

Future Outlook

The RSU grant indicates a continued commitment to the Chief Scientific Officer, suggesting stability in key leadership roles and an incentive for long-term contributions to the company's scientific endeavors.

Industry Context

The grant of Restricted Stock Units to a Chief Scientific Officer is a common and standard practice in the biotechnology and pharmaceutical industries for executive compensation and talent retention. It reflects a strategy to align executive incentives with long-term shareholder value creation, typical for companies like Nurix Therapeutics.

Comparison to Industry Standards

• The grant of 20,000 RSUs to a Chief Scientific Officer is a standard form of equity compensation in the biotech sector, comparable to practices at similar-stage biopharmaceutical companies.
• The two-year vesting schedule is within typical industry ranges for executive RSU grants, balancing immediate incentive with long-term retention goals.

Stakeholder Impact

• Shareholders: Potential future dilution upon the vesting and issuance of common stock from the RSUs.
• Employees (specifically Gwenn Hansen): Increased equity stake and incentive for long-term performance and continued service to the company.

Next Steps

• The RSUs will vest on October 14, 2027, subject to Gwenn Hansen's continuous service.
• Shares of Nurix Therapeutics' common stock will be delivered to Gwenn Hansen following the vesting date.

Key Dates

Recommendation

This Form 4 filing reports a routine executive compensation grant of Restricted Stock Units. It does not contain new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in an investment recommendation. The grant is a standard practice for executive retention and incentive alignment.

Keywords

NRIX, Nurix Therapeutics, Form 4, RSU, Restricted Stock Units, Insider Transaction, Executive Compensation, Gwenn Hansen, Chief Scientific Officer